- Home
- KLTO vs EYEN Comparison
KLTO vs EYEN Comparison
Compare KLTO & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- EYEN
- Stock Information
- Founded
- KLTO 2019
- EYEN 2014
- Country
- KLTO United States
- EYEN United States
- Employees
- KLTO N/A
- EYEN N/A
- Industry
- KLTO
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- EYEN Health Care
- Exchange
- KLTO NYSE
- EYEN Nasdaq
- Market Cap
- KLTO 8.3M
- EYEN 9.2M
- IPO Year
- KLTO N/A
- EYEN 2018
- Fundamental
- Price
- KLTO $0.41
- EYEN $0.06
- Analyst Decision
- KLTO
- EYEN Hold
- Analyst Count
- KLTO 0
- EYEN 4
- Target Price
- KLTO N/A
- EYEN $2.00
- AVG Volume (30 Days)
- KLTO 1.4M
- EYEN 49.5M
- Earning Date
- KLTO 02-15-2025
- EYEN 11-12-2024
- Dividend Yield
- KLTO N/A
- EYEN N/A
- EPS Growth
- KLTO N/A
- EYEN N/A
- EPS
- KLTO N/A
- EYEN N/A
- Revenue
- KLTO N/A
- EYEN $31,832.00
- Revenue This Year
- KLTO N/A
- EYEN $23,413.60
- Revenue Next Year
- KLTO N/A
- EYEN $400.98
- P/E Ratio
- KLTO N/A
- EYEN N/A
- Revenue Growth
- KLTO N/A
- EYEN 2557.10
- 52 Week Low
- KLTO $0.26
- EYEN $0.06
- 52 Week High
- KLTO $13.10
- EYEN $2.57
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- EYEN 35.58
- Support Level
- KLTO N/A
- EYEN $0.06
- Resistance Level
- KLTO N/A
- EYEN $0.09
- Average True Range (ATR)
- KLTO 0.00
- EYEN 0.03
- MACD
- KLTO 0.00
- EYEN 0.00
- Stochastic Oscillator
- KLTO 0.00
- EYEN 1.58
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.